Metrics as of 10/13/2026, 06:47 PM (Berlin time), refresh in progress.
Xeris Biopharma Holdings Stock
Xeris Biopharma Holdings, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- John Shannon
- Employees
- 435
- Market cap
- $1.8 B
- IPO
- 21/06/2018
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company operating within the Healthcare sector and the Biotechnology industry. Headquartered in Chicago, USA, the company focuses on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Xeris Biopharma Holdings stock: price history
1D
-0.4%
1W
+3.5%
1M
+39.9%
6M
+71.7%
YTD
+32.8%
1Y
+31.1%
2Y
+258.1%
5Y
+398.6%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~29% stronger price swings than usual
Ask the agents about Xeris Biopharma Holdings
Analyst assessment of Xeris Biopharma Holdings
PRICE TARGET LOW
US$14.00
CONSENSUS
US$15.00
MEDIAN
US$15.00
PRICE TARGET HIGH
US$16.00
0
STRONG BUY
10
BUY
1
HOLD
0
SELL
0
STRONG SELL
11
TOTAL · Buy
As of: 06/10/2026
Xeris Biopharma Holdings stock metrics
P/E
-106.95
P/B
-184.38
EV/EBITDA
118.19
RETURN ON EQUITY
319.5%
NET MARGIN
-33.8%
DEBT/EQUITY
-29.74
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
95.4%
FLOAT SHARES
164,661,968
AVG. DAILY VOLUME (30D)
2,830,244
Insider transactions (SEC)
Hecht Beth
Pieper Steven
McCulloch Kevin
McCulloch Kevin
Hecht Beth
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -0.4%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Xeris Biopharma Holdings stock
What does Xeris Biopharma Holdings do?
Xeris Biopharma Holdings, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is John Shannon, the company employs around 435 people.
The IPO was on 21/06/2018; the stock trades on NASDAQ under the ticker XERS.
What do analysts say about Xeris Biopharma Holdings stock?
11 analysts rate the stock, the consensus is Buy (as of 06/10/2026).
The average price target is US$15.00, ranging from US$14.00 to US$16.00, with a median of US$15.00.
This is an external assessment, not a statement by Market Jury.
When does Xeris Biopharma Holdings report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 29% stronger than usual.
Does Xeris Biopharma Holdings pay a dividend?
No, Xeris Biopharma Holdings currently does not pay a dividend.
Which stocks are comparable to Xeris Biopharma Holdings?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Xeris Biopharma Holdings stock analyzed?
Clicking "Analyze stock" lets five strategies assess Xeris Biopharma Holdings against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.